Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing - PubMed (original) (raw)
Comparative Study
. 2014 Oct 10;346(6206):256-9.
doi: 10.1126/science.1256930.
Junya Fujimoto 2, Jianhua Zhang 3, David C Wedge 4, Xingzhi Song 3, Jiexin Zhang 5, Sahil Seth 3, Chi-Wan Chow 2, Yu Cao 6, Curtis Gumbs 6, Kathryn A Gold 7, Neda Kalhor 8, Latasha Little 6, Harshad Mahadeshwar 3, Cesar Moran 8, Alexei Protopopov 3, Huandong Sun 3, Jiabin Tang 3, Xifeng Wu 9, Yuanqing Ye 9, William N William 7, J Jack Lee 10, John V Heymach 11, Waun Ki Hong 7, Stephen Swisher 12, Ignacio I Wistuba 2, P Andrew Futreal 13
Affiliations
- PMID: 25301631
- PMCID: PMC4354858
- DOI: 10.1126/science.1256930
Comparative Study
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang et al. Science. 2014.
Abstract
Cancers are composed of populations of cells with distinct molecular and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH). ITH in lung cancers has not been well studied. We applied multiregion whole-exome sequencing (WES) on 11 localized lung adenocarcinomas. All tumors showed clear evidence of ITH. On average, 76% of all mutations and 20 out of 21 known cancer gene mutations were identified in all regions of individual tumors, which suggested that single-region sequencing may be adequate to identify the majority of known cancer gene mutations in localized lung adenocarcinomas. With a median follow-up of 21 months after surgery, three patients have relapsed, and all three patients had significantly larger fractions of subclonal mutations in their primary tumors than patients without relapse. These data indicate that a larger subclonal mutation fraction may be associated with increased likelihood of postsurgical relapse in patients with localized lung adenocarcinomas.
Copyright © 2014, American Association for the Advancement of Science.
Figures
Fig. 1
Assessment of ITH of 11 lung adenocarcinomas by multi-region sequencing. An example of regional mutation distribution (case 330) of resected tumors (represented by the ellipsis) is shown at the up left corner. Mutated cancer genes are indicated to the right of representative H&E image of each sequenced tumor region. Numbers of trunk, branch and private branch mutations for each region are indicated in associated windows. A phylogenetic tree was generated from all validated mutations utilizing Wagner parsimony method in PHYLIP. Blue, yellow and red lines represent trunk, branch and private branches respectively. Trees are anchored at germline DNA sequence obtained from peripheral blood of the relevant patients. Known cancer gene mutations are mapped to the trunks and branches as indicated. Point mutations, amplifications and deletions of known cancer genes are presented as black, +red and −green respectively. Trunk and branch lengths are proportional to the numbers of mutations acquired on the corresponding trunk or branch. Note: 5 tumors have their trunk lengths reduced to 10%S or 2%SS of original length for visualization purposes.
Fig. 2
Distribution of trunk, branch and private branch mutations defined by exome sequencing (average sequencing depth of 277×) versus deep sequencing (average sequencing depth of 863×). Only validated mutations meeting the following criteria are included: total counts in tumor DNA≥100; total counts in germ line DNA≥50; variant allele frequency (VAF) ≥5% in tumor DNA and VAF=0 in germ line DNA.
Fig. 3
Mutation spectrum of the 11 lung adenocarcinomas. (A) Mutation spectrum of all validated mutations. (B) Mutation spectrum of trunk mutations. (C) Mutation spectrum of non-trunk mutations. The difference of mutation spectrum between trunk and non-trunk mutations in each patient was evaluated with Fisher’s exact test and significant p values are shown as *(P<0.05) and **(P<0.01). (D) APOBEC mutation signature enrichment odds ratio for trunk and non-trunk mutations. 95% confidence intervals for Fisher’s exact test are indicated. PY: pack year. ¶: Patient had cut down to 2 cigarettes a day at the time of cancer diagnosis.
Comment in
- Cancer. Attack of the clones.
Govindan R. Govindan R. Science. 2014 Oct 10;346(6206):169-70. doi: 10.1126/science.1259926. Science. 2014. PMID: 25301605 No abstract available. - Lung cancer: Heterogeneity in space and time.
Errico A. Errico A. Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.186. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348786 No abstract available.
Similar articles
- DNA methylation intratumor heterogeneity in localized lung adenocarcinomas.
Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, Little L, Chow CW, Song X, Behrens C, Chen T, William WN, Swisher S, Heymach J, Wistuba I, Zhang J, Futreal A, Zhang J. Quek K, et al. Oncotarget. 2017 Mar 28;8(13):21994-22002. doi: 10.18632/oncotarget.15777. Oncotarget. 2017. PMID: 28423542 Free PMC article. - TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. Reuben A, et al. Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21. Cancer Discov. 2017. PMID: 28733428 Free PMC article. - Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.
Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Francisco-Cruz A, et al. Mod Pathol. 2023 Jan;36(1):100028. doi: 10.1016/j.modpat.2022.100028. Mod Pathol. 2023. PMID: 36788067 Free PMC article. - Deciphering intratumor heterogeneity using cancer genome analysis.
Ryu D, Joung JG, Kim NK, Kim KT, Park WY. Ryu D, et al. Hum Genet. 2016 Jun;135(6):635-42. doi: 10.1007/s00439-016-1670-x. Epub 2016 Apr 28. Hum Genet. 2016. PMID: 27126234 Review. - Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Marusyk A, Janiszewska M, Polyak K. Marusyk A, et al. Cancer Cell. 2020 Apr 13;37(4):471-484. doi: 10.1016/j.ccell.2020.03.007. Cancer Cell. 2020. PMID: 32289271 Free PMC article. Review.
Cited by
- Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer.
Li C, Nguyen TT, Li JR, Song X, Fujimoto J, Little L, Gumb C, Chow CB, Wistuba II, Futreal AP, Zhang J, Hubert SM, Heymach JV, Wu J, Amos CI, Zhang J, Cheng C. Li C, et al. NPJ Precis Oncol. 2024 Oct 5;8(1):225. doi: 10.1038/s41698-024-00680-0. NPJ Precis Oncol. 2024. PMID: 39369068 Free PMC article. - Non-small-cell lung cancer.
Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G, Reck M. Hendriks LEL, et al. Nat Rev Dis Primers. 2024 Sep 26;10(1):71. doi: 10.1038/s41572-024-00551-9. Nat Rev Dis Primers. 2024. PMID: 39327441 Review. - Resolving tumor evolution: a phylogenetic approach.
Li L, Xie W, Zhan L, Wen S, Luo X, Xu S, Cai Y, Tang W, Wang Q, Li M, Xie Z, Deng L, Zhu H, Yu G. Li L, et al. J Natl Cancer Cent. 2024 Mar 21;4(2):97-106. doi: 10.1016/j.jncc.2024.03.001. eCollection 2024 Jun. J Natl Cancer Cent. 2024. PMID: 39282584 Free PMC article. Review. - The role of metabolic reprogramming in immune escape of triple-negative breast cancer.
Bao R, Qu H, Li B, Cheng K, Miao Y, Wang J. Bao R, et al. Front Immunol. 2024 Aug 13;15:1424237. doi: 10.3389/fimmu.2024.1424237. eCollection 2024. Front Immunol. 2024. PMID: 39192979 Free PMC article. Review. - Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Piha-Paul SA, et al. NPJ Precis Oncol. 2024 Jul 31;8(1):166. doi: 10.1038/s41698-024-00634-6. NPJ Precis Oncol. 2024. PMID: 39085400 Free PMC article.
References
- Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012 Mar 28;4:127ps10. - PubMed
- Horswell S, Matthews N, Swanton C. Cancer heterogeneity and “The Struggle for Existence”: Diagnostic and analytical challenges. Cancer Lett. 2012 Nov 8; - PubMed
Publication types
MeSH terms
Grants and funding
- P30 CA016672/CA/NCI NIH HHS/United States
- T32 CA-009666/CA/NCI NIH HHS/United States
- CA016672/CA/NCI NIH HHS/United States
- P50CA70907/CA/NCI NIH HHS/United States
- P50 CA070907/CA/NCI NIH HHS/United States
- T32 CA009666/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous